689 related articles for article (PubMed ID: 20448661)
1. The genetic basis of kidney cancer: a metabolic disease.
Linehan WM; Srinivasan R; Schmidt LS
Nat Rev Urol; 2010 May; 7(5):277-85. PubMed ID: 20448661
[TBL] [Abstract][Full Text] [Related]
2. The metabolic basis of kidney cancer.
Linehan WM; Ricketts CJ
Semin Cancer Biol; 2013 Feb; 23(1):46-55. PubMed ID: 22705279
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis and therapy of kidney cancer.
Linehan WM; Bratslavsky G; Pinto PA; Schmidt LS; Neckers L; Bottaro DP; Srinivasan R
Annu Rev Med; 2010; 61():329-43. PubMed ID: 20059341
[TBL] [Abstract][Full Text] [Related]
4. The prospect of precision therapy for renal cell carcinoma.
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F
Cancer Treat Rev; 2016 Sep; 49():37-44. PubMed ID: 27453294
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
6. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy.
Pfaffenroth EC; Linehan WM
Expert Opin Biol Ther; 2008 Jun; 8(6):779-90. PubMed ID: 18476789
[TBL] [Abstract][Full Text] [Related]
7. [Genetic backgrounds of renal cell carcinoma].
Oya M
Nihon Rinsho; 2006 Feb; 64 Suppl 2():593-6. PubMed ID: 16523961
[No Abstract] [Full Text] [Related]
8. Genetic predisposition to kidney cancer.
Schmidt LS; Linehan WM
Semin Oncol; 2016 Oct; 43(5):566-574. PubMed ID: 27899189
[TBL] [Abstract][Full Text] [Related]
9. The genetic basis of cancer of the kidney.
Linehan WM; Walther MM; Zbar B
J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
[TBL] [Abstract][Full Text] [Related]
10. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
Maher ER
World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Maina E; Morgan NV; Gentle D; Astuti D; Moch H; Kishida T; Yao M; Schraml P; Richards FM; Latif F; Maher ER
J Clin Pathol; 2004 Jul; 57(7):706-11. PubMed ID: 15220362
[TBL] [Abstract][Full Text] [Related]
12. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
13. Hereditary kidney cancer syndromes.
Haas NB; Nathanson KL
Adv Chronic Kidney Dis; 2014 Jan; 21(1):81-90. PubMed ID: 24359990
[TBL] [Abstract][Full Text] [Related]
14. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
15. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
16. Pseudohypoxic pathways in renal cell carcinoma.
Bratslavsky G; Sudarshan S; Neckers L; Linehan WM
Clin Cancer Res; 2007 Aug; 13(16):4667-71. PubMed ID: 17699843
[TBL] [Abstract][Full Text] [Related]
17. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
[TBL] [Abstract][Full Text] [Related]
18. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
[TBL] [Abstract][Full Text] [Related]
20. Hereditary kidney cancer: unique opportunity for disease-based therapy.
Linehan WM; Pinto PA; Bratslavsky G; Pfaffenroth E; Merino M; Vocke CD; Toro JR; Bottaro D; Neckers L; Schmidt LS; Srinivasan R
Cancer; 2009 May; 115(10 Suppl):2252-61. PubMed ID: 19402075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
